85.26 USD
-2.67 (-3.04%)
Overall LMAT gets a fundamental rating of 7 out of 10. We evaluated LMAT against 188 industry peers in the Health Care Equipment & Supplies industry. LMAT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. LMAT has a decent growth rate and is not valued too expensively. With these ratings, LMAT could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
LMAT had positive earnings in the past year.
LMAT had a positive operating cash flow in the past year.
In the past 5 years LMAT has always been profitable.
Each year in the past 5 years LMAT had a positive operating cash flow.
1.2 Ratios
LMAT has a Return On Assets of 8.92%. This is amongst the best in the industry. LMAT outperforms 90.96% of its industry peers.
The Return On Equity of LMAT (14.08%) is better than 89.89% of its industry peers.
The Return On Invested Capital of LMAT (8.43%) is better than 86.70% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 8.71%.
The last Return On Invested Capital (8.43%) for LMAT is above the 3 year average (8.26%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROIC | 8.43% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
Looking at the Profit Margin, with a value of 22.14%, LMAT belongs to the top of the industry, outperforming 93.62% of the companies in the same industry.
LMAT's Profit Margin has improved in the last couple of years.
The Operating Margin of LMAT (25.71%) is better than 95.74% of its industry peers.
LMAT's Operating Margin has improved in the last couple of years.
LMAT's Gross Margin of 70.97% is fine compared to the rest of the industry. LMAT outperforms 78.72% of its industry peers.
In the last couple of years the Gross Margin of LMAT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, LMAT has more shares outstanding
LMAT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LMAT has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.44 indicates that LMAT is not in any danger for bankruptcy at the moment.
LMAT has a Altman-Z score of 7.44. This is amongst the best in the industry. LMAT outperforms 86.70% of its industry peers.
The Debt to FCF ratio of LMAT is 2.54, which is a good value as it means it would take LMAT, 2.54 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of LMAT (2.54) is better than 85.64% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that LMAT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.44, LMAT perfoms like the industry average, outperforming 45.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Altman-Z | 7.44 |
ROIC/WACC0.99
WACC8.5%
2.3 Liquidity
A Current Ratio of 13.58 indicates that LMAT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.58, LMAT belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
LMAT has a Quick Ratio of 11.45. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT has a better Quick ratio (11.45) than 96.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.67% over the past year.
Measured over the past years, LMAT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.13% on average per year.
The Revenue has grown by 13.07% in the past year. This is quite good.
The Revenue has been growing by 13.41% on average over the past years. This is quite good.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
3.2 Future
LMAT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.76% yearly.
Based on estimates for the next years, LMAT will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y9.76%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.67%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 38.93, LMAT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, LMAT is valued a bit cheaper than 70.21% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.47, LMAT is valued quite expensively.
Based on the Price/Forward Earnings ratio of 33.64, the valuation of LMAT can be described as expensive.
Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than the industry average as 70.74% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 34.42. LMAT is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.93 | ||
| Fwd PE | 33.64 |
4.2 Price Multiples
73.94% of the companies in the same industry are more expensive than LMAT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, LMAT is valued a bit cheaper than the industry average as 78.72% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.15 | ||
| EV/EBITDA | 20.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
LMAT's earnings are expected to grow with 12.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.95
PEG (5Y)2.27
EPS Next 2Y14.3%
EPS Next 3Y12.64%
5. Dividend
5.1 Amount
With a yearly dividend of 0.95%, LMAT is not a good candidate for dividend investing.
LMAT's Dividend Yield is rather good when compared to the industry average which is at 1.74. LMAT pays more dividend than 93.09% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, LMAT's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
5.2 History
On average, the dividend of LMAT grows each year by 13.60%, which is quite nice.
LMAT has paid a dividend for at least 10 years, which is a reliable track record.
LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
32.20% of the earnings are spent on dividend by LMAT. This is a low number and sustainable payout ratio.
LMAT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
NASDAQ:LMAT (11/24/2025, 1:32:28 PM)
85.26
-2.67 (-3.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.25%
Inst Owner Change-3.92%
Ins Owners7.8%
Ins Owner Change-5.67%
Market Cap1.93B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.75
Price Target106.42 (24.82%)
Short Float %5.83%
Short Ratio7.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.42%
PT rev (3m)-0.42%
EPS NQ rev (1m)4.28%
EPS NQ rev (3m)4.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)-2.08%
Revenue NQ rev (3m)-2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.93 | ||
| Fwd PE | 33.64 | ||
| P/S | 8.01 | ||
| P/FCF | 29.15 | ||
| P/OCF | 26.34 | ||
| P/B | 5.09 | ||
| P/tB | 6.86 | ||
| EV/EBITDA | 20.75 |
EPS(TTM)2.19
EY2.57%
EPS(NY)2.53
Fwd EY2.97%
FCF(TTM)2.93
FCFY3.43%
OCF(TTM)3.24
OCFY3.8%
SpS10.64
BVpS16.74
TBVpS12.42
PEG (NY)1.95
PEG (5Y)2.27
Graham Number28.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROCE | 10.97% | ||
| ROIC | 8.43% | ||
| ROICexc | 21.47% | ||
| ROICexgc | 38.36% | ||
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% | ||
| FCFM | 27.5% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 68.51% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.46% | ||
| Profit Quality | 124.17% | ||
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 | ||
| Altman-Z | 7.44 |
F-Score5
WACC8.5%
ROIC/WACC0.99
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y19.93%
EPS Next 2Y14.3%
EPS Next 3Y12.64%
EPS Next 5Y9.76%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year13.86%
Revenue Next 2Y11.2%
Revenue Next 3Y10.46%
Revenue Next 5Y9.67%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year43.57%
EBIT Next 3Y22.42%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%
LEMAITRE VASCULAR INC / LMAT FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
Can you provide the valuation status for LEMAITRE VASCULAR INC?
ChartMill assigns a valuation rating of 4 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 38.93 and the Price/Book (PB) ratio is 5.09.
What is the expected EPS growth for LEMAITRE VASCULAR INC (LMAT) stock?
The Earnings per Share (EPS) of LEMAITRE VASCULAR INC (LMAT) is expected to grow by 19.93% in the next year.